BusinessWire

CynergisTek Reports Third Quarter 2020 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--$CTEK #compliance--CynergisTek, Inc. (NYSE AMERICAN: CTEK), a leader in cybersecurity, privacy, and compliance, today announced financial results for the three and nine months ended September 30, 2020.


Recent Operational Highlights

  • Expense reduction, delivery efficiency and restructuring initiatives drove improvements in operating results despite COVID-19 headwinds
    • Sequentially for Q3 versus Q2, gross margins improved to 35% from 27%; net loss improved by $1.2 million and Adjusted EBITDA improved by $0.6 million
    • Q3 Net loss and EPS remained flat compared with prior year

“We continued to execute on our plans to streamline the organization, improve delivery efficiency and reduce operating expenses through the quarter and those efforts are reflected in the improvements from the second quarter to the third quarter,” said Caleb Barlow, President and CEO of CynergisTek.

“As the headwinds of COVID-19 continue to impact the healthcare industry, we are pleased to see positive results from our investments in sales and marketing, as evidenced by the new wins in the third quarter, improvements in our pipeline and positive sales momentum as we near the end of the year.”

For the Three Months Ended September 30, 2020, Compared to the Three Months Ended September 30, 2019

Revenue was $4.5 million for the three months ended September 30, 2020, as compared to $4.8 million in the same period in 2019. Managed Services revenue decreased $0.4 million to $2.7 million due to the impact of some customers canceling or delaying renewals and a slowdown in net new customers due to healthcare providers responding to the negative impact from and uncertainty surrounding the impact from COVID-19. Consulting and professional services revenue increased $0.1 million to $1.8 million due to $0.8 million in new consulting and professional services revenues from the acquisition of Backbone.

Gross margin was 35% of revenue for the three months ended September 30, 2020, compared to 34% for the same period in 2019. This increase was a result staff and expense reductions we made over the last couple quarters in reaction to lower revenue.

Sales and marketing expenses increased to $1.3 million for the three months ended September 30, 2020 due to the addition of Backbone. General and administrative expenses decreased $0.2 million to $1.5 million for the three months ended September 30, 2020. The decrease is due to $0.4 million in expense reductions enacted to improve operating margins offset by the additional costs from Backbone.

GAAP net loss from continuing operations for the three months ended September 30, 2020 was $1.3 million, or $0.12 per basic and diluted share compared to a net loss of $1.3 million, or $0.13 per basic and diluted share for the same period of 2019.

Non-GAAP adjusted EBITDA loss was $0.8 million for the three months ended September 30, 2020, compared to a loss of $0.4 million for the same period in 2019.

The reconciliation of GAAP to non-GAAP information can be found in the table at the end of this release and provides the detail of the Company’s non-GAAP disclosures and the reconciliation of non-GAAP information.

Use of Non-GAAP Measures

CynergisTek, Inc. prepares its consolidated financial statements in accordance with generally accepted accounting principles (“GAAP”). In addition to disclosing financial results prepared in accordance with GAAP, the Company discloses information regarding Adjusted EBITDA, which differs from the term EBITDA as it is commonly used. In addition to adjusting net income (loss) to exclude income taxes, interest, and depreciation and amortization, Adjusted EBITDA also excludes share-based compensation, impairment charges, fair value adjustments, severance, and other cash and non-cash charges and gains.

Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. However, Adjusted EBITDA is used internally in planning and evaluating the Company’s operating performance. Accordingly, management believes that disclosure of this metric offers investors, bankers and other stakeholders an additional view of the Company’s operations that, when coupled with the GAAP results, provides a more complete understanding of the Company’s financial results.

Adjusted EBITDA should not be considered as an alternative to loss from continuing operations or to net cash used in operating activities as measures of operating results or liquidity. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures used by other companies, and the measures exclude financial information that some may consider important in evaluating the Company’s performance.

Adjusted EBITDA has limitations as analytical tools, and you should not consider them in isolation, or as substitutes for analysis of our results as reported under GAAP. Some of these limitations are (i) it does not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments, (ii) it does not reflect changes in, or cash requirements for, our working capital needs, (iii) Adjusted EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debt, (iv) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA do not reflect any cash requirements for such replacements, (v) it does not adjust for all non-cash income or expense items that are reflected in our statements of cash flows, (vi) it does not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations, and (vii) other companies in our industry may calculate this measure differently than we do, limiting its usefulness as a comparative measure.

We believe Adjusted EBITDA facilitates operating performance comparisons from period to period by isolating the effects of some items that vary from period to period without any correlation to core operating performance or that vary widely among similar companies. These potential differences may be caused by variations in capital structures (affecting interest expense), tax positions (such as the impact on periods or companies of changes in effective tax rates or net operating losses) and the age and book depreciation of facilities and equipment (affecting relative depreciation expense). We also present Adjusted EBITDA because (i) we believe this measures is frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry, (ii) we believe investors will find this measure useful in assessing our ability to service or incur indebtedness, and (iii) we use Adjusted EBITDA internally as a benchmark to evaluate our operating performance or compare our performance to that of our competitors.

Conference Call Information

Date: Thursday, November 12th, 2020
Time: 4:30 pm ET / 1:30 pm PT

U.S.: 1-866-269-4260
International: 1-786-204-3977
Conference ID: 8233178
Webcast: http://public.viavid.com/index.php?id=142245

A replay of the call will be available from Thursday November 12, 2020, 7:30 PM ET to Thursday November 19, 2020, 11:59 PM ET. To access the replay, please dial 1-844-512-2921 from the U.S. and 1-412-317-6671 from outside the U.S. The PIN is 8233178.

About CynergisTek, Inc.

CynergisTek is a top-ranked cybersecurity firm dedicated to serving the information assurance needs of the healthcare industry. CynergisTek offers specialized services and solutions to help organizations achieve privacy, security, and compliance goals. Since 2004, the company has served as a partner to hundreds of healthcare organizations and is dedicated to supporting and educating the industry by contributing to relevant industry associations. The company has been recognized by KLAS as a top performing firm in healthcare cybersecurity and was awarded the 2019 Top Healthcare Cybersecurity Consultants in Black Book IT Advisory Outcomes Survey.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of CynergisTek. These forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “may” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product/services development, long and uncertain sales cycles, the ability to obtain or maintain proprietary intellectual property protection, market acceptance, future capital requirements, competition from other providers, the ability of our vendors to continue supplying the company with equipment, parts, supplies and services at comparable terms and prices, potential risks and uncertainties relating to the ultimate impact of COVID-19, including the geographic spread, the severity of the disease, the duration of the COVID-19 outbreak, actions that may be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact, and the potential negative impacts of COVID-19 on the global economy and financial markets, and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. CynergisTek is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

CYNERGISTEK, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

September 30,
2020 (unaudited)

December 31,
2019

ASSETS

 

 

Current assets:

 

 

Cash and cash equivalents

$ 4,287,162

$ 5,328,726

Accounts receivable

1,898,434

3,210,726

Unbilled services

697,322

539,535

Prepaid and other current assets

1,377,628

1,205,769

Income taxes receivable

1,478,933

-

Total current assets

9,739,479

10,284,756

 

 

 

Property and equipment, net

710,949

946,219

Deposits

64,586

72,486

Deferred income taxes

1,949,716

1,836,258

Intangible assets, net

7,337,308

8,585,882

Goodwill

23,983,483

23,983,483

Total assets

$ 43,785,521

$ 45,709,084

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

Current liabilities:

 

 

Accounts payable and accrued expenses

$ 802,002

$ 638,864

Accrued compensation and benefits

544,412

1,066,770

Deferred revenue

1,555,277

1,437,859

Income taxes payable

-

31,976

Current portion of promissory note to related parties

562,500

562,500

Current portion of Paycheck Protection Program loan

1,714,946

-

Current portion of operating lease

370,565

533,371

Total current liabilities

5,549,702

4,271,340

 

 

 

Long-term liabilities:

 

 

Earnout liability

2,400,000

2,400,000

Promissory note to related parties, less current portion

281,250

703,125

Paycheck Protection Program loan, less current portion

1,110,554

-

Operating lease, less current portion

64,725

158,995

Total long-term liabilities

3,856,529

3,262,120

 

 

 

Commitments and contingencies

 

 

 

 

 

Stockholders’ equity:

 

 

Common stock, par value at $0.001, 33,333,333 shares authorized, 10,597,024 shares issued and outstanding at September 30, 2020, and 10,359,164 shares issued and outstanding at December 31, 2019

10,596

10,359

Additional paid-in capital

36,606,975

34,821,863

(Accumulated deficit) Retained earnings

(2,238,281)

3,343,402

Total stockholders’ equity

34,379,290

38,175,624

Total liabilities and stockholders’ equity

$ 43,785,521

$ 45,709,084

CYNERGISTEK, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

Three Months Ended
September 30,

Nine Months Ended
September 30,

 

2020

2019

2020

2019

Net revenues

$ 4,502,909

$ 4,766,000

$ 14,176,307

$ 15,597,117

Cost of revenues

2,909,788

3,165,502

9,679,816

9,613,777

Gross profit

1,593,121

1,600,498

4,496,491

5,983,340

 

Operating expenses:

 

 

 

 

Sales and marketing

1,325,965

1,090,733

4,490,797

3,907,847

General and administrative

1,480,597

1,689,012

5,381,929

4,807,789

Change in valuation of contingent earnout

-

(178,269)

-

(178,269)

Depreciation

48,296

47,775

141,668

135,875

Amortization of acquisition-related intangibles

416,191

452,734

1,248,574

1,358,202

Finance cost for equity commitment

-

-

390,000

-

Total operating expenses

3,271,049

3,101,985

11,652,968

10,031,444

Loss from operations

(1,677,928)

(1,501,487)

(7,156,477)

(4,048,104)

 

Other income (expense):

 

 

 

 

Other income

-

-

-

26

Interest income

1,868

41,438

9,543

58,076

Interest expense

(26,046)

(30,459)

(77,654)

(439,909)

Loss on disposition of fixed assets

 

(2,188)

 

(2,188)

Total other (expense) income

(24,179)

8,791

(68,110)

(383,995)

 

 

 

 

 

Loss before provision for income taxes

(1,702,107)

(1,492,696)

(7,224,586)

(4,432,099)

Income tax benefit

425,708

236,040

1,642,902

746,778

Net loss from continuing operations

(1,276,399)

(1,256,656)

(5,581,684)

(3,685,321)

(Loss) income from discontinued operations, including gain on sale, net of tax

-

(6,500)

-

18,878,149

Net (loss) income

$ (1,276,399)

$ (1,263,156)

$ (5,581,684)

$ 15,192,828

 

 

 

 

 

Net (loss) income per share:

 

 

 

 

From continuing operations:

 

 

 

 

Basic

$ (0.12)

$ (0.13)

$ (0.53)

$ (0.38)

Diluted

$ (0.12)

$ (0.13)

$ (0.53)

$ (0.38)

 

 

 

 

 

From discontinued operations:

 

 

 

 

Basic

$ -

$ -

$ -

$ 1.94

Diluted

$ -

$ -

$ -

$ 1.90

 

 

 

 

 

Net (loss) income:

 

 

 

 

Basic

$ (0.12)

$ (0.13)

$ (0.53)

$ 1.56

Diluted

$ (0.12)

$ (0.13)

$ (0.53)

$ 1.53

 

 

 

 

 

Number of weighted average shares outstanding:

 

 

 

 

Basic

10,597,024

9,795,147

10,486,334

9,754,014

Diluted

10,597,024

9,795,147

10,486,334

9,910,107

CYNERGISTEK, INC. AND SUBSIDIARIES

RECONCILIATION OF GAAP LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA FROM CONTINUING OPERATIONS

(UNAUDITED)

 

Three Months Ended September 30,

 

2020

2019

GAAP loss from continuing operations

$ (1,677,928)

$ (1,501,486)

Adjustments:

 

 

Depreciation

48,296

47,775

Amortization of acquisition-related intangibles

416,191

452,734

Non-recurring restructuring and legal costs

79,000

300,000

Stock-based compensation

378,077

325,600

Non-GAAP adjusted EBITDA

$ (756,364)

$ (375,377)

Non-GAAP adjusted EBITDA per share

 

 

Basic

$ (0.07)

$ (0.04)

Diluted

$ (0.07)

$ (0.04)

 


Contacts

Investor Relations Contact:
Paul Anthony
(949) 382-1419
InvestorRelations@CynergisTek.com

Media Contact:
Allison + Partners
Jaime Tero
415-755-8639
jaime.tero@allisonpr.com